SpotitEarly, an Israeli medical technology startup, is revolutionizing oncology diagnostics by deploying trained dogs and artificial intelligence to identify four major cancers from human breath samples with a 94% success rate. This breakthrough screening method, validated in a double-blind clinical study involving 1,400 participants, targets the early detection of breast, colorectal, prostate, and lung cancers—the most prevalent forms of the disease globally.
Scientific Validation and Strategic U.S. Expansion
The company’s methodology gained significant scientific weight following a study published in Nature’s Scientific Reports. This research confirms that canine olfactory precision can reliably distinguish malignant chemical signatures at an early stage. To scale this innovation, SpotitEarly secured $20.3 million in funding from a high-profile investor group, including Hanaco VC, Menomedin VC, former Timberland CEO Jeff Swartz, and Wix.com CEO Avishai Abrahami. This capital infusion facilitates the company’s official entry into the United States market.
Disrupting Oncology with Accessible At-Home Testing
SpotitEarly plans to utilize its new capital to broaden clinical trials, beginning with specialized tests for breast cancer before rolling out the full multi-cancer panel. The company aims to make these screenings commercially available through a physician network by next year. A primary competitive advantage lies in the pricing structure; an initial cancer test will cost approximately $250, with supplemental screenings priced at a fraction of that amount. This strategy positions SpotitEarly as a cost-effective alternative to existing multi-cancer early detection (MCED) tests, such as Grail’s Galleri, which typically costs consumers around $950.
The Synergy of Biological Sensors and Animal Welfare
While the dogs function as high-precision biosensors, CEO Ariel Madar emphasizes that the animals remain integral members of the corporate team. SpotitEarly maintains a strict organizational culture where all employees must be “dog people,” ensuring the animals operate in a supportive environment with ample space for play and social interaction. By merging biological excellence with AI-driven analysis, the startup transforms canine companionship into a sophisticated frontline defense against cancer.
